Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Number of metastatic organs negatively affects the treatment sequence in patients with EGFR-TKI failure.

Thoracic cancer - 1 Apr 2020

Mizuno Takaaki, Horinouchi Hidehito, Watanabe Sho, Sato Jun, Morita Ryo, Murakami Shuji, Goto Yasushi, Kanda Shintaro, Fujiwara Yutaka, Yamamoto Noboru, Ohe Yuichiro

Abstract excerpt

BACKGROUND: Several studies have previously demonstrated the survival benefit of both EGFR-TKI treatment and chemotherapy in patients with non-small cell lung cancer (NSCLC) harboring EGFR mutations. The aim of the present study was to clarify the factors influencing the treatment sequence after failure of EGFR-TKI therapy, focusing on the number of organs with metastasis (hereafter, metastatic organs). METHODS:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Squamous Cell

Share to ErbB Receptors

Share to Follow-Up Studies

Share to Neoplasm Metastasis

Share to Protein Kinase Inhibitors

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 32077630
DOI: 10.1111/1759-7714.13360
PMCID: PMC7113048

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Number of metastatic organs negatively affects the treatment sequence in patients with EGFR-TKI failure.PMID 32077630Read ↗

Readministration of EGFR tyrosine kinase inhibitor in non-small cell lung cancer patients after initial failure, what affects its efficacy?Semantic proximity Read ↗

Converging Survival Trends in Non-Small Cell Lung Cancer Patients With and Without Brain Metastasis Receiving State-of-the-Art TreatmentSemantic proximity Read ↗

Converging survival trends in non-small cell lung cancer patients with and without brain metastasis receiving state-of-the-art treatment.Semantic proximity Read ↗

Impact of central nervous system metastasis after complete resection of lung adenocarcinomas harboring common EGFR mutation - A real-world database study in Japan: The CReGYT-01 EGFR study.Semantic proximity Read ↗

Prognosis of different bone metastases patterns in EGFR-mutant advanced lung adenocarcinoma patientsSemantic proximity Read ↗

Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer.Semantic proximity Read ↗

Clinical Impact of Post-Progression Survival on Overall Survival in Elderly Patients with Non-Small-Cell Lung Cancer Harboring Sensitive EGFR Mutations Treated with First-Line EGFR Tyrosine Kinase Inhibitors.Semantic proximity Read ↗

Impact of metastatic status on the prognosis of EGFR mutation‑positive non‑small cell lung cancer patients treated with first‑generation EGFR‑tyrosine kinase inhibitorsSemantic proximity Read ↗

Analysis of Progression Patterns and Failure Sites of Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations Receiving First-line Treatment of Tyrosine Kinase Inhibitors.Semantic proximity Read ↗

Analysis of non-small cell lung cancer with miliary lung metastasis in patients harboring epidermal growth factor receptor mutations.Semantic proximity Read ↗

Clinical Implications of Isolated Bone Failure Without Systemic Disease Progression During EGFR-TKI Treatment.Semantic proximity Read ↗

T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.